These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 17684823)

  • 1. To nuke, or not to nuke?
    Proj Inf Perspect; 2007 Apr; (43):1-3. PubMed ID: 17684823
    [No Abstract]   [Full Text] [Related]  

  • 2. Choosing which nuke to use first.
    TreatmentUpdate; 2001; 12(12):3-4. PubMed ID: 11570090
    [No Abstract]   [Full Text] [Related]  

  • 3. Protection from nuke side effects.
    TreatmentUpdate; 2002 Dec; 14(9):3-4. PubMed ID: 12593383
    [No Abstract]   [Full Text] [Related]  

  • 4. Lactic acid and nuke damage.
    TreatmentUpdate; 2002 Nov; 14(8):5-6. PubMed ID: 12501824
    [No Abstract]   [Full Text] [Related]  

  • 5. Assessing nuke toxicity.
    TreatmentUpdate; 2002 Mar; 14(3):3-4. PubMed ID: 12033187
    [No Abstract]   [Full Text] [Related]  

  • 6. Warning against tenofovir + ddI + 3TC, and "triple nuke" combinations.
    AIDS Treat News; 2003 Oct; (395):2-3. PubMed ID: 14666910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons from two "triple nuke" failures (new training module).
    AIDS Treat News; 2004 Mar; (399):6. PubMed ID: 15199869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-HIV agents. Non-nukes and the brain.
    TreatmentUpdate; 2007 Jan; 19(1):6. PubMed ID: 17390479
    [No Abstract]   [Full Text] [Related]  

  • 9. Skin lesions as another possible clinical manifestation of mitochondrial toxicity in an HIV-infected patient.
    Bachmeyer C; Orlandini V; Grimaldi D; Bonnard P; Moguelet P; Aractingi S
    Dermatology; 2007; 214(2):189-90. PubMed ID: 17341874
    [No Abstract]   [Full Text] [Related]  

  • 10. Apricitabine continues to show good results.
    Dalton P
    Proj Inf Perspect; 2008 Sep; (46):12. PubMed ID: 19043879
    [No Abstract]   [Full Text] [Related]  

  • 11. NNRTI without the rash.
    Susman E
    AIDS; 2002 Aug; 16(12):N8. PubMed ID: 12214592
    [No Abstract]   [Full Text] [Related]  

  • 12. Mitochondrial toxicity.
    Rodriguez A
    Women Alive; 2001; ():16. PubMed ID: 11683004
    [No Abstract]   [Full Text] [Related]  

  • 13. Side effects and complications. Uridine finally gets tested in people.
    TreatmentUpdate; 2005 Dec; 17(7):4-6. PubMed ID: 17223670
    [No Abstract]   [Full Text] [Related]  

  • 14. Two new NNRTIs enter the pipeline.
    Dalton P
    Proj Inf Perspect; 2008 Sep; (46):13. PubMed ID: 19048672
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial comment: reversing lipoatrophy--better solutions needed.
    McComsey G
    AIDS Read; 2004 Dec; 14(12):648-9. PubMed ID: 15619780
    [No Abstract]   [Full Text] [Related]  

  • 16. Nonnucleotide reverse-transcriptase inhibitors and treatment interruption.
    DiNubile MJ
    Clin Infect Dis; 2008 Dec; 47(12):1602; author reply 1603. PubMed ID: 19025367
    [No Abstract]   [Full Text] [Related]  

  • 17. Nucleoside analogues in 2008.
    Warwick Z; Churchill D
    J HIV Ther; 2008 Mar; 13(1):3-8. PubMed ID: 18953267
    [No Abstract]   [Full Text] [Related]  

  • 18. Researcher presents vexing information on rilpivirine.
    Dalton P
    Proj Inf Perspect; 2008 Sep; (46):10-2. PubMed ID: 19048650
    [No Abstract]   [Full Text] [Related]  

  • 19. [Reliable effectiveness for years with good long-term tolerance: 10 years nevirapine--a summary].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():70. PubMed ID: 19024921
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibitors of HIV-1 reverse transcriptase.
    Ilina T; Parniak MA
    Adv Pharmacol; 2008; 56():121-67. PubMed ID: 18086411
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.